Anakinra
- Generic Name
- Anakinra
- Brand Names
- Kineret
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 143090-92-0
- Unique Ingredient Identifier
- 9013DUQ28K
- Background
Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta. Anakinra is indicated for the managemen...
- Indication
Anakinra is an interleukin-1 receptor antagonist indicated for the reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis (RA), in patients 18 years of age or older who have failed one or more disease-modifying antirheumatic drugs (DMARDs). Anakinra can be used alone or in combin...
- Associated Conditions
- Coronavirus Disease 2019 (COVID‑19), Cryopyrin-associated Periodic Syndromes (CAPS), Deficiency of the interleukin-1 receptor antagonist, Idiopathic Recurrent Pericarditis, Moderately to Severely Active Rheumatoid Arthritis, Neonatal-Onset Multisystem Inflammatory Disease (NOMID), Systemic Juvenile Idiopathic Arthritis (SJIA)
- Associated Therapies
- -
Fatigue and Interleukin-1 (IL-1) Blockade in Primary Sjøgrens Syndrome
- First Posted Date
- 2008-05-23
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- Helse Stavanger HF
- Target Recruit Count
- 28
- Registration Number
- NCT00683345
- Locations
- 🇳🇴
Stavanger University Hospital, Stavanger, Norway
Anti-inflammatory Therapy With Anakinra in Newly Diagnosed Type 1 Diabetes
- First Posted Date
- 2008-03-28
- Last Posted Date
- 2019-11-14
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 15
- Registration Number
- NCT00645840
- Locations
- 🇺🇸
Children's Medical Center, Dallas, Texas, United States
The SPECTRA Study
- Conditions
- Interventions
- First Posted Date
- 2007-10-01
- Last Posted Date
- 2009-11-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 22
- Registration Number
- NCT00537667
Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS
- Conditions
- First Posted Date
- 2006-06-20
- Last Posted Date
- 2010-07-20
- Target Recruit Count
- 24
- Registration Number
- NCT00339157
- Locations
- 🇫🇷
Pediatric Immuno-Hematology and Rheumatology Unit, Necker-Enfants Malades Hospital, 149 rue de Sevres, Paris, France
🇫🇷Kremlin-Bicetre Hospital, Kremlin-Bicetre, France
🇫🇷Bordeaux CHU, Bordeaux, France
Study to Prevent Cartilage Damage Following Acute Knee Injury.
- First Posted Date
- 2006-06-01
- Last Posted Date
- 2013-05-30
- Lead Sponsor
- Duke University
- Target Recruit Count
- 10
- Registration Number
- NCT00332254
- Locations
- 🇺🇸
Duke University Sports Medicine Clinic, Durham, North Carolina, United States
Treatment of Patients With Type 2 Diabetes With an Interleukin-1 Antagonist
- Conditions
- First Posted Date
- 2006-03-16
- Last Posted Date
- 2007-03-05
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 72
- Registration Number
- NCT00303394
- Locations
- 🇨🇭
University Hospital of Zurich, Division of Endocrinology and Diabetes, Zurich, Switzerland
🇩🇰Steno Diabetes Center, Gentofte, Copenhagen, Denmark
Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease
- Conditions
- Interventions
- First Posted Date
- 2003-09-23
- Last Posted Date
- 2016-12-01
- Target Recruit Count
- 43
- Registration Number
- NCT00069329
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Evaluation of the Efficacy of Combination Treatment With Anakinra and Pegsunercept in Improving Rheumatoid Arthritis
- Conditions
- First Posted Date
- 2002-05-21
- Last Posted Date
- 2009-11-26
- Lead Sponsor
- Amgen
- Registration Number
- NCT00037700
Juvenile Rheumatoid Arthritis
- First Posted Date
- 2002-05-20
- Last Posted Date
- 2009-11-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 86
- Registration Number
- NCT00037648
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.